FDA In Brief: FDA Enhances Purple Book to Support Transparency in Biosimilars | FDA

FDA In Brief: FDA Enhances Purple Book to Support Transparency in Biosimilars | FDA

FDA In Brief: FDA Enhances Purple Book toSupport Transparency in Biosimilars

The following quote is attributed to FDA Commissioner Stephen M. Hahn, M.D.:

“This expansion and digitization of the Purple Book will make more information about FDA-licensed biological products more accessible, increasing transparency for patients, industry users and other stakeholders. “We’re confident these enhancements will meet the needs of a wide range of users, from providing a simple search for patients and consumers, to a more advanced search for prescribers, researchers and industry representatives that may have a need for more technical information. “Providing stakeholders with more information about biological products through a modernized platform should better facilitate the acceptance and use of existing biosimilar products and the development of new ones, potentially leading to lower costs for patients and improved access to safe, effective, high-quality medications.”